Cargando…

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

BACKGROUND: Several studies have reported discordant results regarding the impact of the CYP2D6 phenotype on both the effectiveness and the degree of endocrine symptoms associated with tamoxifen. Other studies have suggested that menopausal symptoms may be a predictive factor to tamoxifen response....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sestak, I, Kealy, R, Nikoloff, M, Fontecha, M, Forbes, J F, Howell, A, Cuzick, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394993/ https://www.ncbi.nlm.nih.gov/pubmed/22735900 http://dx.doi.org/10.1038/bjc.2012.278

Ejemplares similares

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
por: Forbes, John F, et al.
Publicado: (2016)

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
por: Sestak, Ivana, et al.
Publicado: (2021)

The pharmacological and hormonal therapy of hot flushes in breast cancer survivors
por: Wiśniewska, Iwona, et al.
Publicado: (2015)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
por: Sestak, I, et al.
Publicado: (2018)

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ
por: Lo, Louisa Lisa, et al.
Publicado: (2018)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
por: Smith, Samuel G., et al.
Publicado: (2021)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
por: Thomas, R, et al.
Publicado: (2008)

Estimating the Risks and Benefits of Tamoxifen for Prophylactic Breast Cancer Chemoprevention in Korea
por: Kim, Dong Uk, et al.
Publicado: (2012)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
por: Cuzick, Jack, et al.
Publicado: (2015)

Hot flushes, hypertension and haemodialysis
por: de Zoysa, Janak R., et al.
Publicado: (2011)

Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis
por: Chien, Tsai-Ju, et al.
Publicado: (2017)

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials
por: Cuzick, Jack, et al.
Publicado: (2017)

Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study
por: Sung, Sumi, et al.
Publicado: (2022)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

Improving decision making about clinical trial participation – a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial
por: Juraskova, I, et al.
Publicado: (2014)

Herbal Medicine for Hot Flushes Induced by Endocrine Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis
por: Li, Yuanqing, et al.
Publicado: (2016)

Effect of Soy Isoflavone on Hot Flushes, Endometrial Thickness, and Breast Clinical as well as Sonographic Features
por: VAHID DASTJERDI, Marziyeh, et al.
Publicado: (2018)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
por: Brooks, Jennifer D., et al.
Publicado: (2018)

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2020)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908)

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen
por: Jansen, Maurice P.H.M., et al.
Publicado: (2016)

Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
por: Cruz, Aline, et al.
Publicado: (2017)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
por: Damkier, Per, et al.
Publicado: (2017)

Hot flushes and quality of life during menopause
por: Luoto, Riitta
Publicado: (2009)

CGRP Is Critical for Hot Flushes in Ovariectomized Mice
por: Wilhelms, Daniel B., et al.
Publicado: (2019)

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
por: Chamnanphon, Montri, et al.
Publicado: (2013)

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
por: Love, Richard R, et al.
Publicado: (2013)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
por: Sirachainan, Ekaphop, et al.
Publicado: (2012)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_trvoq6njg0138u2f60n0msdmd5